Appointment of Representative Director, President & CEO

We are pleased to announce that, following the Extraordinary General Meeting of Shareholders and the subsequent Board resolution held on November 25, 2025, Mr. Ryota Sakurai, a Director of the Company and former Representative Director and President of Organon Japan, has been appointed as Representative Director, President and Chief Executive Officer.

Under the new management structure, Sanodyne will be managed by co-representative directors, Ryota Sakurai and Kazuhiko Nonomura, and accelerate the development of our lead asset, SNT-001, to promptly deliver it to patients suffering from peripheral neuropathy.

Comments from Ryota Sakurai

“Chronic pain is increasingly recognized as a major societal challenge, on par with lifestyle-related diseases and mental health disorders. I am proud to have joined our company in addressing this pressing issue.

Our lead asset, SNT-001, is a novel small-molecule compound with a completely new mechanism of action. It holds the potential to deliver disease-modifying effects and to bring true innovation to the treatment of peripheral neuropathy and neuropathic pain.

Through close collaboration with diverse stakeholders, we remain committed to delivering SNT-001 and other new therapeutic options to patients who suffers from chronic pain as swiftly as possible.”

We sincerely appreciate your continued support.